NPCE
NeuroPace Inc

330
Mkt Cap
$485.63M
Volume
68,640.00
52W High
$18.98
52W Low
$7.56
PE Ratio
-19.35
NPCE Fundamentals
Price
$14.58
Prev Close
$15.02
Open
$14.82
50D MA
$15.78
Beta
1.16
Avg. Volume
248,047.25
EPS (Annual)
-$0.9318
P/B
26.20
Rev/Employee
$434,271.74
$346.51
Loading...
Loading...
News
all
press releases
LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates
LivaNova (LIVN) delivered earnings and revenue surprises of +7.06% and +2.84%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
More News
News Placeholder
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4d ago
News Placeholder
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NeuroPace (NPCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·5d ago
News Placeholder
NeuroPace (NPCE) Projected to Post Earnings on Tuesday
NeuroPace (NASDAQ:NPCE) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 3. (View Earnings Report at...
MarketBeat·6d ago
News Placeholder
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of...
Business Wire·9d ago
News Placeholder
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of +36.84% and +9.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm, Marketbeat...
MarketBeat·1mo ago
News Placeholder
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported preliminary unaudited results for the fourth quarter ended...
Business Wire·2mo ago
News Placeholder
NeuroPace (NASDAQ:NPCE) Sees Strong Trading Volume - Here's Why
NeuroPace (NASDAQ:NPCE) Sees Unusually-High Trading Volume - Should You Buy...
MarketBeat·2mo ago
News Placeholder
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 44th Annual...
Business Wire·2mo ago
<
1
2
...
>

Latest NPCE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.